Dexcom [DXCM] vs Boston Scientific [BSX] Detailed Stock Comparison
Dexcom
NASDAQ
Loading...
Boston Scientific
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Dexcom wins in 6 metrics, Boston Scientific wins in 13 metrics, with 0 ties. Boston Scientific appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Dexcom | Boston Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 56.46 | 61.41 | Dexcom |
| Price-to-Book Ratio | 12.22 | 6.81 | Boston Scientific |
| Debt-to-Equity Ratio | 100.24 | 53.09 | Boston Scientific |
| PEG Ratio | 39.49 | 0.42 | Boston Scientific |
| EV/EBITDA | 33.67 | 34.98 | Dexcom |
| Profit Margin (TTM) | 13.29% | 13.55% | Boston Scientific |
| Operating Margin (TTM) | 18.37% | 18.63% | Boston Scientific |
| EBITDA Margin (TTM) | 18.37% | 18.63% | Boston Scientific |
| Return on Equity | 22.83% | 11.55% | Dexcom |
| Return on Assets (TTM) | 6.08% | 5.39% | Dexcom |
| Free Cash Flow (TTM) | $630.70M | $2.37B | Boston Scientific |
| 1-Year Return | 8.44% | 31.85% | Boston Scientific |
| Price-to-Sales Ratio (TTM) | 7.31 | 8.27 | Dexcom |
| Enterprise Value | $31.09B | $164.60B | Boston Scientific |
| EV/Revenue Ratio | 7.23 | 8.90 | Dexcom |
| Gross Profit Margin (TTM) | 59.53% | 67.65% | Boston Scientific |
| Revenue per Share (TTM) | $11 | $13 | Boston Scientific |
| Earnings per Share (Diluted) | $1.42 | $1.68 | Boston Scientific |
| Beta (Stock Volatility) | 1.44 | 0.66 | Boston Scientific |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Dexcom vs Boston Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Dexcom | 1.24% | 2.65% | -4.52% | -5.51% | -10.58% | 3.12% |
| Boston Scientific | -0.94% | 0.03% | -0.30% | -1.61% | -2.07% | 15.43% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Dexcom | 8.44% | -4.89% | -24.15% | 259.78% | 2,494.55% | 2,653.40% |
| Boston Scientific | 31.85% | 145.53% | 168.46% | 531.01% | 1,713.18% | 274.35% |
Performance & Financial Health Analysis: Dexcom vs Boston Scientific
| Metric | DXCM | BSX |
|---|---|---|
| Market Information | ||
| Market Cap | $31.44B | $152.87B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 5,083,030 | 5,810,696 |
| 90 Day Avg. Volume | 3,546,350 | 7,116,939 |
| Last Close | $80.95 | $103.17 |
| 52 Week Range | $57.52 - $93.25 | $76.60 - $108.94 |
| % from 52W High | -13.19% | -5.30% |
| All-Time High | $164.86 (Nov 15, 2021) | $108.94 (Jul 23, 2025) |
| % from All-Time High | -50.90% | -5.30% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.15% | 0.23% |
| Quarterly Earnings Growth | 0.25% | 1.46% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.14% |
| Operating Margin (TTM) | 0.18% | 0.19% |
| Return on Equity (TTM) | 0.23% | 0.12% |
| Debt to Equity (MRQ) | 100.24 | 53.09 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.56 | $15.14 |
| Cash per Share (MRQ) | $7.47 | $0.36 |
| Operating Cash Flow (TTM) | $987.70M | $4.28B |
| Levered Free Cash Flow (TTM) | $425.12M | $2.94B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Dexcom vs Boston Scientific
| Metric | DXCM | BSX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 56.46 | 61.41 |
| Forward P/E | 39.49 | 36.98 |
| PEG Ratio | 39.49 | 0.42 |
| Price to Sales (TTM) | 7.31 | 8.27 |
| Price to Book (MRQ) | 12.22 | 6.81 |
| Market Capitalization | ||
| Market Capitalization | $31.44B | $152.87B |
| Enterprise Value | $31.09B | $164.60B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.23 | 8.90 |
| Enterprise to EBITDA | 33.67 | 34.98 |
| Risk & Other Metrics | ||
| Beta | 1.44 | 0.66 |
| Book Value per Share (MRQ) | $6.56 | $15.14 |
Financial Statements Comparison: Dexcom vs Boston Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DXCM | BSX |
|---|---|---|
| Revenue/Sales | $1.04B | $4.66B |
| Cost of Goods Sold | $447.00M | $1.45B |
| Gross Profit | $589.00M | $3.21B |
| Research & Development | $145.20M | $443.00M |
| Operating Income (EBIT) | $133.70M | $937.00M |
| EBITDA | $219.00M | $1.23B |
| Pre-Tax Income | $154.30M | $805.00M |
| Income Tax | $48.90M | $133.00M |
| Net Income (Profit) | $105.40M | $672.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DXCM | BSX |
|---|---|---|
| Cash & Equivalents | $904.90M | $725.00M |
| Total Current Assets | $4.55B | $7.34B |
| Total Current Liabilities | $3.04B | $5.06B |
| Long-Term Debt | $1.36B | $10.93B |
| Total Shareholders Equity | $2.27B | $22.45B |
| Retained Earnings | $1.70B | $3.35B |
| Property, Plant & Equipment | $59.10M | $448.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DXCM | BSX |
|---|---|---|
| Operating Cash Flow | $167.90M | $513.00M |
| Capital Expenditures | $-87.00M | $-187.00M |
| Free Cash Flow | $96.80M | $277.00M |
| Debt Repayment | N/A | $-1.31B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | DXCM | BSX |
|---|---|---|
| Shares Short | 8.49M | 16.27M |
| Short Ratio | 2.71 | 2.15 |
| Short % of Float | 0.03% | 0.01% |
| Average Daily Volume (10 Day) | 5,083,030 | 5,810,696 |
| Average Daily Volume (90 Day) | 3,546,350 | 7,116,939 |
| Shares Outstanding | 390.70M | 1.47B |
| Float Shares | 389.43M | 1.48B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.99% | 0.94% |
Dividend Analysis & Yield Comparison: Dexcom vs Boston Scientific
| Metric | DXCM | BSX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |